Blincyto blinatumomab: Additional Phase III data

Additional data from the open-label, international Phase III TOWER trial in 405 patients with Ph- relapsed or refractory B cell precursor ALL showed that IV Blincyto led to a median OS, the primary endpoint, of 7.7 months vs. 4 months for investigator’s choice of 1 of 4 protocol-defined standard of care (SOC) chemotherapy regimens (HR=0.71, p=0.012). Data were presented at the European Hematology Association meeting in Copenhagen. Amgen previously reported that the trial was stopped early after a pre-specified interim analysis by an IDMC showed that Blincyto met the primary endpoint (see BioCentury, Feb. 15). ...